RJA
UTHR icon

Ross\Johnson & Associates’s United Therapeutics UTHR Stock Holding History

Ross\Johnson & Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542 Buy
+1
New +$563 0.01% 127
2025
Q2 		– Sell
-2
Closed -$617 – 341
2025
Q1 		$617 Buy
+2
New +$685 0.01% 236

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Ross\Johnson & Associates's UTHR Position: Q2 2026 in Review

Ross\Johnson & Associates opened a new position in United Therapeutics (UTHR) in Q2 2026: 1 share worth $542. The stake represents 0.01% of the portfolio and ranks #127 among its holdings. This is a return to the name: Ross\Johnson & Associates previously reported a position in UTHR as recently as Q1 2025.

Ross\Johnson & Associates first reported a position in UTHR in Q1 2025 and has held it in 2 quarters since. The position peaked at $617 in Q1 2025. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Ross\Johnson & Associates held 1 share of United Therapeutics worth $542 as of Q2 2026.
  • United Therapeutics was a new Ross\Johnson & Associates position in Q2 2026.
  • United Therapeutics made up 0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #127 holding.
  • Ross\Johnson & Associates first reported a position in United Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • Ross\Johnson & Associates's United Therapeutics position peaked at $617 in Q1 2025.
  • 881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.